
    
      This is a phase II, two stage, single arm, open label, multi-center study of oral PAN in
      combination with BTZ/Dex in patients with relapsed and refractory multiple myeloma, who are
      bortezomib-refractory and have received at least 2 prior lines of therapy. Patients must have
      been exposed to an iMID (lenalidomide or thalidomide) and progressed on or within 60 days of
      their last BTZ-containing line of therapy.
    
  